In other types of gynecologic cancers, TLR9 pathway activates lymphocyte T cell shift towards Th1 profile and decreases the number of MDSCs, TAMs and Tregs in the TME, displaying anti-tumor properties [133]. Here, TLR9 is linked to neoplasm.